Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK MHRA Aims To Cast Early Access Scheme In New Light

Agency Wants To Make EAMS More Attractive To Sponsors Of Innovative Medicines

Executive Summary

The UK’s Early Access to Medicines Scheme continues to provide important flexibility, but companies also now have the option of a new ambitious pathway launched this year for accelerating time to market for innovative medicines.

You may also be interested in...



UK Wants Early Access Scheme To Remain ‘Relevant And Attractive’ Following Brexit

The MHRA has drawn up measures to improve regulatory certainty around the UK’s early patient access scheme while reducing regulatory burden in certain areas of its operation.

Can The UK Remain A First Launch Market?

More political support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.

UK Vaunts 'New Era' In Drug Approvals

The UK regulator, the MHRA, has published guidance on its new integrated pathway for innovative drug approvals, which it says is intended to bring together partners including health technology assessment agencies, health care bodies and patient organizations to offer “sustained collaboration” with drug developers.

Topics

UsernamePublicRestriction

Register

PS144749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel